

Laurent Savale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5680192/publications.pdf>

Version: 2024-02-01

100
papers

6,676
citations

76196

40
h-index

64668

79
g-index

101
all docs

101
docs citations

101
times ranked

6877
citing authors

#	ARTICLE	IF	CITATIONS
1	Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. <i>Circulation</i> , 2012, 125, 2128-2137.	1.6	548
2	Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2017, 50, 1700889.	3.1	527
3	Four-Month Clinical Status of a Cohort of Patients After Hospitalization for COVID-19. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1525.	3.8	434
4	A Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease. <i>New England Journal of Medicine</i> , 2011, 365, 44-53.	13.9	432
5	Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study. <i>European Respiratory Journal</i> , 2014, 43, 1691-1697.	3.1	319
6	Endothelial cell dysfunction: a major player in SARS-CoV-2 infection (COVID-19)?. <i>European Respiratory Journal</i> , 2020, 56, 2001634.	3.1	284
7	Portopulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 637-643.	2.5	220
8	Criteria for diagnosis of exercise pulmonary hypertension. <i>European Respiratory Journal</i> , 2015, 46, 728-737.	3.1	213
9	French experience of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1802095.	3.1	173
10	Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2018, 137, 693-704.	1.6	155
11	Chemotherapy-Induced Pulmonary Hypertension. <i>American Journal of Pathology</i> , 2015, 185, 356-371.	1.9	149
12	Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension. <i>European Respiratory Journal</i> , 2019, 53, 1801906.	3.1	144
13	Pulmonary vascular endothelium: the orchestra conductor in respiratory diseases. <i>European Respiratory Journal</i> , 2018, 51, 1700745.	3.1	136
14	Ectopic upregulation of membrane-bound IL6R drives vascular remodeling in pulmonary arterial hypertension. <i>Journal of Clinical Investigation</i> , 2018, 128, 1956-1970.	3.9	125
15	Initial dual oral combination therapy in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016, 47, 1727-1736.	3.1	124
16	Macitentan for the treatment of portopulmonary hypertension (PORTICO): a multicentre, randomised, double-blind, placebo-controlled, phase 4 trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 594-604.	5.2	119
17	Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. <i>European Respiratory Journal</i> , 2017, 50, 1700465.	3.1	111
18	Post-acute COVID-19 syndrome. <i>European Respiratory Review</i> , 2022, 31, 210185.	3.0	105

#	ARTICLE	IF	CITATIONS
19	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 842-854.	2.5	94
20	Efficacy, safety and pharmacokinetics of bosentan in portopulmonary hypertension. <i>European Respiratory Journal</i> , 2013, 41, 96-103.	3.1	92
21	Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: An observational study. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 150-158.	0.3	91
22	Characteristics and outcomes of asthmatic patients with COVID-19 pneumonia who require hospitalisation. <i>European Respiratory Journal</i> , 2020, 56, 2001875.	3.1	90
23	Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. <i>European Respiratory Journal</i> , 2017, 50, 1700217.	3.1	89
24	Genetic counselling in a national referral centre for pulmonary hypertension. <i>European Respiratory Journal</i> , 2016, 47, 541-552.	3.1	87
25	External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. <i>European Respiratory Journal</i> , 2022, 59, 2102419.	3.1	83
26	De-novo donor-specific anti-HLA antibodies 30 days after lung transplantation are associated with a worse outcome. <i>Journal of Heart and Lung Transplantation</i> , 2016, 35, 1067-1077.	0.3	81
27	Selective BMP-9 Inhibition Partially Protects Against Experimental Pulmonary Hypertension. <i>Circulation Research</i> , 2019, 124, 846-855.	2.0	81
28	Pulmonary arterial hypertension in patients treated with interferon. <i>European Respiratory Journal</i> , 2014, 44, 1627-1634.	3.1	80
29	Portopulmonary hypertension in the current era of pulmonary hypertension management. <i>Journal of Hepatology</i> , 2020, 73, 130-139.	1.8	78
30	Long-term outcome in liver transplantation candidates with portopulmonary hypertension. <i>Hepatology</i> , 2017, 65, 1683-1692.	3.6	68
31	Lung transplantation for scleroderma lung disease: An international, multicenter, observational cohort study. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 903-911.	0.3	64
32	Haemodynamics and serial risk assessment in systemic sclerosis associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2018, 52, 1800678.	3.1	60
33	Screening for pulmonary arterial hypertension in systemic sclerosis. <i>European Respiratory Review</i> , 2019, 28, 190023.	3.0	59
34	Loss of Vascular Distensibility During Exercise Is an Early Hemodynamic Marker of Pulmonary Vascular Disease. <i>Chest</i> , 2016, 149, 353-361.	0.4	55
35	Neutralization of CXCL12 attenuates established pulmonary hypertension in rats. <i>Cardiovascular Research</i> , 2020, 116, 686-697.	1.8	54
36	Pulmonary vascular remodeling patterns and expression of general control nonderepressible 2 (GCN2) in pulmonary veno-occlusive disease. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 647-655.	0.3	50

#	ARTICLE	IF	CITATIONS
37	Screening for pulmonary arterial hypertension in adults carrying a <i>BMPR2</i> mutation. <i>European Respiratory Journal</i> , 2021, 58, 2004229.	3.1	50
38	Acute decompensated pulmonary hypertension. <i>European Respiratory Review</i> , 2017, 26, 170092.	3.0	48
39	Pulmonary Hypertension Complicating Fibrosing Mediastinitis. <i>Medicine (United States)</i> , 2015, 94, e1800.	0.4	46
40	Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity. <i>European Respiratory Journal</i> , 2016, 48, 1517-1519.	3.1	44
41	Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission. <i>European Respiratory Journal</i> , 2021, 58, 2100116.	3.1	41
42	Phenotype and outcome of pulmonary arterial hypertension patients carrying a <i>TBX4</i> mutation. <i>European Respiratory Journal</i> , 2020, 55, 1902340.	3.1	40
43	Rapid onset honeycombing fibrosis in spontaneously breathing patient with COVID-19. <i>European Respiratory Journal</i> , 2020, 56, 2001808.	3.1	38
44	Pulmonary arterial hypertension in patients treated with interferon. <i>European Respiratory Journal</i> , 2015, 46, 1851-1853.	3.1	35
45	Lung transplantation for sarcoidosis: outcome and prognostic factors. <i>European Respiratory Journal</i> , 2021, 58, 2003358.	3.1	32
46	Portopulmonary Hypertension. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2017, 38, 651-661.	0.8	30
47	Central versus peripheral cannulation of extracorporeal membrane oxygenation support during double lung transplant for pulmonary hypertension. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 54, 341-347.	0.6	30
48	Impact of High-Priority Allocation on Lung and Heart-Lung Transplantation for Pulmonary Hypertension. <i>Annals of Thoracic Surgery</i> , 2017, 104, 404-411.	0.7	29
49	Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors. <i>European Respiratory Journal</i> , 2020, 56, 2000279.	3.1	28
50	Serum and pulmonary uric acid in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2021, 58, 2000332.	3.1	28
51	WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension. <i>European Respiratory Review</i> , 2022, 31, 210165.	3.0	28
52	Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 13-26.	1.0	27
53	Different cardiovascular and pulmonary phenotypes for single- and double-knock-out mice deficient in BMP9 and BMP10. <i>Cardiovascular Research</i> , 2022, 118, 1805-1820.	1.8	26
54	Intensity and quality of exertional dyspnoea in patients with stable pulmonary hypertension. <i>European Respiratory Journal</i> , 2020, 55, 1802108.	3.1	24

#	ARTICLE	IF	CITATIONS
55	Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension. <i>Cardiovascular Research</i> , 2021, 117, 1391-1401.	1.8	23
56	Therapeutic effect of pirfenidone in the sugen/hypoxia rat model of severe pulmonary hypertension. <i>FASEB Journal</i> , 2019, 33, 3670-3679.	0.2	22
57	Precision medicine and personalising therapy in pulmonary hypertension: seeing the light from the dawn of a new era. <i>European Respiratory Review</i> , 2018, 27, 180004.	3.0	21
58	Macrophage Migration Inhibitory Factor (MIF) Inhibition in a Murine Model of Bleomycin-Induced Pulmonary Fibrosis. <i>International Journal of Molecular Sciences</i> , 2018, 19, 4105.	1.8	21
59	Chronic blood exchange transfusions in the management of pre-capillary pulmonary hypertension complicating sickle cell disease. <i>European Respiratory Journal</i> , 2018, 52, 1800272.	3.1	21
60	Multidisciplinary approach for post-acute COVID-19 syndrome: time to break down the walls. <i>European Respiratory Journal</i> , 2021, 58, 2101090.	3.1	18
61	ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1135-1194.	0.3	17
62	Pulmonary arterial hypertension populations of special interest: portopulmonary hypertension and pulmonary arterial hypertension associated with congenital heart disease. <i>European Heart Journal Supplements</i> , 2019, 21, K37-K45.	0.0	16
63	Respiratory symptoms and radiological findings in post-acute COVID-19 syndrome. <i>ERJ Open Research</i> , 2022, 8, 00479-2021.	1.1	16
64	Clinical phenotypes and outcomes of precapillary pulmonary hypertension of sickle cell disease. <i>European Respiratory Journal</i> , 2019, 54, 1900585.	3.1	15
65	Glucocorticoids with low-dose anti-IL1 anakinra rescue in severe non-ICU COVID-19 infection: A cohort study. <i>PLoS ONE</i> , 2020, 15, e0243961.	1.1	15
66	An emerging phenotype of pulmonary arterial hypertension patients carrying <i>SOX17</i> variants. <i>European Respiratory Journal</i> , 2022, 60, 2200656.	3.1	15
67	Characteristics and Long-term Outcomes of Pulmonary Venocclusive Disease Induced by Mitomycin C. <i>Chest</i> , 2021, 159, 1197-1207.	0.4	14
68	Outcomes of patients with decreased arterial oxyhaemoglobin saturation on pulmonary arterial hypertension drugs. <i>European Respiratory Journal</i> , 2021, 58, 2004066.	3.1	14
69	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 843-852.	2.5	12
70	Chronic thromboembolic pulmonary hypertension and totally implantable central venous access systems. <i>European Respiratory Journal</i> , 2021, 57, 2002208.	3.1	12
71	Cardiovascular disorders in patients with congenital portosystemic shunts: 23 years of experience in a tertiary referral centre. <i>Archives of Cardiovascular Diseases</i> , 2021, 114, 221-231.	0.7	11
72	Clinical and Hemodynamic Correlates of Pulmonary Arterial Stiffness in Incident, Untreated Patients With Idiopathic Pulmonary Arterial Hypertension. <i>Chest</i> , 2018, 154, 882-892.	0.4	10

#	ARTICLE	IF	CITATIONS
73	Congenital portosystemic shunts. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 452-459.	0.7	10
74	Five-year survival after an acute episode of decompensated pulmonary arterial hypertension in the modern management era of right heart failure. <i>European Respiratory Journal</i> , 2021, 58, 2100466.	3.1	7
75	Lung transplantation in HIV-positive patients: a European retrospective cohort study. <i>European Respiratory Journal</i> , 2022, 60, 2200189.	3.1	7
76	Risk stratification in patients with pulmonary arterial hypertension at the time of listing for lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 1285-1293.	0.3	6
77	Risks and outcomes of gastrointestinal endoscopy with anaesthesia in patients with pulmonary hypertension. <i>British Journal of Anaesthesia</i> , 2020, 125, e466-e468.	1.5	5
78	The isobaric pulmonary arterial compliance in pulmonary hypertension. <i>ERJ Open Research</i> , 2021, 7, 00941-2020.	1.1	5
79	Cardiovascular phenotypes predict clinical outcomes in sickle cell disease: An echocardiography-based cluster analysis. <i>American Journal of Hematology</i> , 2021, 96, 1166-1175.	2.0	5
80	Outcomes of cirrhotic patients with pre-capillary pulmonary hypertension and pulmonary vascular resistance between 2 and 3 Wood Units. <i>European Respiratory Journal</i> , 2022, 60, 2200107.	3.1	5
81	Pumpless Lung Assist as a Bridge to Medical Therapy in a Teenager With Pulmonary Arterial Hypertension and Partial Anomalous Pulmonary Venous Return. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1831.e7-1831.e9.	0.8	4
82	Portopulmonary Hypertension. <i>Chest</i> , 2012, 141, 840-842.	0.4	3
83	Our current understanding of and approach to the management of lung cancer with pulmonary hypertension. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 373-384.	1.0	3
84	Reversible pulmonary hypertension associated with multivisceral Whipple's disease. <i>European Respiratory Journal</i> , 2021, 57, 2003132.	3.1	3
85	Pulmonary Hypertension in Patients with Common Variable Immunodeficiency. <i>Journal of Clinical Immunology</i> , 2021, 41, 1549-1562.	2.0	3
86	Transplantation for pulmonary arterial hypertension with congenital heart disease: Impact on outcomes of the current therapeutic approach including a high-priority allocation program. <i>American Journal of Transplantation</i> , 2021, 21, 3388-3400.	2.6	3
87	Pulmonary hypertension associated with busulfan. <i>Pulmonary Circulation</i> , 2021, 11, 1-12.	0.8	3
88	Double-lung transplantation followed by delayed percutaneous repair for atrial septal defect-associated pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2022, 59, 2102388.	3.1	3
89	Sequential combination therapy with parenteral prostacyclin in BMPR2 mutations carriers. <i>Pulmonary Circulation</i> , 2022, 12, e12023.	0.8	2
90	A <i>CELSR1</i> variant in a patient with pulmonary arterial hypertension. <i>Clinical Genetics</i> , 2021, 100, 771-772.	1.0	1

#	ARTICLE	IF	CITATIONS
91	Endothelial dysfunction and hypercoagulability in severe sickle-cell acute chest syndrome. ERJ Open Research, 2021, 7, 00496-2021.	1.1	1
92	Reappraising the effects of pulmonary artery wedge pressure on right ventricular pulsatile loading. , 2018, , .		1
93	Pulmonary Hypertension in Sickle Cell Disease: Current Controversies and Clinical Practices. Respiratory Medicine, 2020, , 123-134.	0.1	1
94	Acute Right-Heart Failure in Patients with Chronic Precapillary Pulmonary Hypertension. , 2021, , 301-316.		0
95	Reply to: Jin et al. and Sun et al.. American Journal of Respiratory and Critical Care Medicine, 2021, , .	2.5	0
96	Right heart failure. , 0, , 32-47.		0
97	Title is missing!. , 2020, 15, e0243961.		0
98	Title is missing!. , 2020, 15, e0243961.		0
99	Title is missing!. , 2020, 15, e0243961.		0
100	Title is missing!. , 2020, 15, e0243961.		0